Engflag

Adipan

Quick links to important sections

Adipan

Adipan_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adipan

Quick Facts

Property Description
Active ingredient Amphetamine (Racemic)
Form Solid, Immediate-Release (IR) Tablet
Pharmacological class Central Nervous System (CNS) Stimulant
General purpose Promote wakefulness and enhance attention
Origin Synthetic (Phenethylamine derivative)

What is Adipan and How is it Classified?

Adipan is a historical trade name associated with a pharmaceutical preparation containing the active ingredient Amphetamine in its racemic form. This medication is classified as a powerful Central Nervous System (CNS) Stimulant and belongs to the therapeutic group known as psychoanaleptics. The compound is entirely synthetic in origin, placing it within the structural class of phenethylamines. This classification aligns with the drug's effect on the central nervous system, identifying its core action as one that is clinically recognized for promoting a state of pronounced arousal and heightened vigilance.

Composition and Physical Form of the Medicine (Type and Form)

The core component of the preparation is Racemic Amphetamine, which denotes an equal mixture of both the Dextro- and Levo- forms of alpha-methylphenethylamine. This single-component product was historically presented in a solid form, specifically as an oral dosage form such as an immediate-release (IR) tablet. The IR characteristic means the medication is designed to deliver the full dose rapidly upon ingestion. The unique inclusion of the Levo-isomer, characteristic of the racemic formulation, contributes to both the central stimulating effects and noticeable peripheral sympathomimetic actions.

What is the General Purpose of This Type of Stimulant? (High-Level Benefit)

The general purpose of a medicine classified as a CNS stimulant is to produce a profound increase in wakefulness and mental energy. The physiological effect of activating the brain's arousal systems translates directly to the general benefit of improving an individual’s capacity for sustained attention and enhancing cognitive control. The drug achieves this by modulating monoamine neurotransmission, making it useful in scenarios that require maintaining high levels of concentration and remaining significantly alert.

What side effects are possible with Adipan?

Possible Side Effects and Safety Information

Adipan, containing racemic amphetamine, has an official safety profile categorized by regulatory authorities to communicate documented risks, from expected effects to severe adverse reactions. The medicine is formally classified as having a High Potential for Abuse and dependence, a constraint highlighted in government prescribing information.

Adverse reactions are grouped by the affected System-Organ Class. Most Common effects, often reported with an incidence of 5% or more in clinical studies, include dry mouth, loss of appetite, insomnia, and headache. Other effects frequently reported involve Gastrointestinal Disorders (e.g., nausea, abdominal pain) and Psychiatric Disorders (e.g., anxiety, agitation, emotional lability).

Serious adverse reactions documented in regulatory sources include the rare but severe risks of Sudden Death, Stroke, and Myocardial Infarction (heart attack), especially in patients with pre-existing structural cardiac abnormalities. Treatment can also be associated with the emergence of Psychotic or Manic Symptoms and the risk of Serotonin Syndrome.

Population-specific safety considerations are explicitly defined. For the pediatric population, there is a documented potential for growth suppression (height and weight deficits) with long-term, continuous use. Furthermore, amphetamine is present in breast milk, and official guidance advises nursing mothers to refrain from breastfeeding. Official regulatory documents list conditions such as severe cardiovascular disease, moderate-to-severe hypertension, and glaucoma as formal contraindications for use.

Overdose and Emergency Response

Overdose of Adipan (Racemic Amphetamine) is defined by severe neuro-sympathomimetic manifestations resulting from excessive exposure to this Central Nervous System stimulant. Observable signs include tachyarrhythmias, pronounced hypertension or hypotension, psychomotor agitation, confusion, hallucinations, and hyperreflexia. Gastrointestinal effects such as nausea, vomiting, and abdominal cramps may also be present.

Overdose can lead to life-threatening outcomes, and immediate medical attention is required for all severe signs. Documented complications include sudden cardiac death, myocardial infarction, stroke, seizures, coma, and life-threatening hyperthermia. The development of Serotonin syndrome and rhabdomyolysis are also officially noted risks in regulatory documents.

Regulatory guidance mandates that a Certified Poison Control Center be contacted immediately in cases of suspected overdose. Management is strictly symptomatic and supportive, involving close medical supervision, continuous monitoring of cardiac rhythm and vital signs, and ensuring adequate airway and ventilation. It is officially documented that no specific antidote is known for amphetamine overdose.

Therapeutic Uses of Adipan

What Adipan Treats: Main Uses and Benefits

Adipan is commonly used in situations involving certain distressing symptoms related to neurological or muscular activity. It is applied across domains where additional symptomatic support is needed in situations where patients experience functional strain.

The medication is commonly used to help with conditions characterized by periods of heightened symptoms, including Attention-Deficit Hyperactivity Disorder (ADHD) and Narcolepsy, and historically for Obesity. It is relevant for managing symptom clusters that may become intense or disruptive, such as inattention, impulsivity, hyperactivity, and excessive daytime sleepiness (EDS) that create noticeable physiological strain. This symptomatic assistance is commonly applied when short-term symptomatic assistance is needed.

This supportive therapeutic benefit provides supportive relief when symptoms interfere with routine activities. It may assist with maintaining functional stability and supports general well-being during symptomatic phases, helping to ease distress.

Quick Fact: Symptomatic Support Summary

Symptom Domain General Benefit Clinical Context
Inattention / Impulsivity May assist with functional stability ADHD, academic/occupational strain
Excessive Sleepiness Contributes to sustained alertness Narcolepsy, safety-critical scenarios
Appetite (Historical) Eases systemic imbalance Short-term management of appetite

Regulatory References

  1. Amphetamine - StatPearls - NCBI Bookshelf - NIH

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Adipan

Adipan (referring to the CGRP receptor antagonist atogepant, used for migraine prophylaxis) is officially restricted to certain populations based on regulatory documents.

Contraindicated Populations

Use is contraindicated and must be avoided in individuals with a known history of hypersensitivity to the active substance (atogepant) or any of the inactive ingredients. Use is also strictly avoided with the concomitant use of moderate or strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin).

Restricted and Special Populations

Population Eligibility Classification Restriction Basis
Pediatric Population (<18 years) Use Not Established Safety and efficacy have not been established in children and adolescents.
Severe Hepatic Impairment Avoid Use Use is not recommended in patients with severe liver dysfunction.
Severe Renal Impairment / ESRD Restricted / Dose-Limited For severe kidney impairment (CLcr <30 mL/min) and End-Stage Renal Disease, the recommended dosage must be reduced.
Pregnancy and Lactation Not Recommended / Caution Limited data is available; use is generally not recommended during pregnancy unless strictly necessary. It is unknown if the medicine is excreted into human milk.

All individuals for whom use is allowed must be adults who are carefully evaluated for potential drug interactions with CYP3A4 inducers or OATP inhibitors, which may require a dosage adjustment.

What should I know about interactions with other medicines?

The interaction profile for Adipan (Racemic Amphetamine) is governed by pharmacokinetic changes and severe pharmacodynamic risks, as documented in official government labeling.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated. This includes drugs with MAOI activity, such as Linezolid and Intravenous Methylene Blue, due to the high risk of hypertensive crisis. A mandatory separation of at least 14 days is required after stopping an MAOI before Adipan administration.

Pharmacokinetic Interactions

The drug’s clearance and systemic exposure are affected by agents that alter pH. Gastrointestinal and urinary alkalinizing agents (e.g., Sodium Bicarbonate) increase drug blood levels by decreasing excretion, potentially leading to potentiation. Conversely, acidifying agents (e.g., Ascorbic Acid, certain fruit juices) decrease blood levels by increasing excretion and reducing absorption. Furthermore, co-administration with CYP2D6 inhibitors may increase amphetamine exposure due to reduced metabolic clearance.

Pharmacodynamic Interactions

Combining Adipan with other serotonergic drugs (e.g., SSRIs, SNRIs) is associated with an increased risk of Serotonin Syndrome. The drug can also enhance the adrenergic effects of agents like Norepinephrine and potentiate the cardiovascular effects of Tricyclic Antidepressants. Other medicines, such as Chlorpromazine and Lithium, are documented to inhibit or antagonize the stimulant effects.

Mechanism of Action

Targeted Suppression of Gastric Acid Secretion

This mechanism involves pantoprazole's action as a Proton Pump Inhibitor (PPI). It works by covalently and irreversibly binding to the H^+/K^+-ATPase enzyme on the secretory surface of gastric parietal cells, directly inhibiting the final step of HCl production. This action reduces overall gastric acidity by blocking the acid pump activity, establishing a higher gastric and esophageal pH environment.

Regulation of Upper Gastrointestinal Motility

This domain is governed by domperidone's role as a peripheral dopamine receptor antagonist. By blocking D2 receptors in the gut, it facilitates the release of acetylcholine, which, in turn, stimulates coordinated contractions of the stomach and small intestine. This results in faster gastric emptying and increased propulsive force on gastrointestinal contents, affecting the pressure gradient and transit time of contents.

Dosage and Administration Information

How to Use Adipan

Adipan, which contains racemic amphetamine as an immediate-release oral tablet, is administered according to a precise regulatory schedule to manage its approved conditions. The overall usage of the medicine is defined by a detailed administration protocol.

Administration Schedule and Timing

The standard administration route is oral. Dosing is typically conducted using divided doses throughout the day. To prevent certain dose-related effects, the first dose is taken upon awakening, and doses should be avoided in the late evening. For the historical indication of exogenous obesity, administration is further specified to occur 30 to 60 minutes before meals.

Dose Adjustment and Limits

Initial dosing is based on the condition being addressed. For narcolepsy, the dose typically starts at 10 mg daily for patients 12 years and older, with a maximum daily limit of 60 mg. The dose is adjusted through a process of titration, where the amount may be raised in 5 mg or 10 mg increments at weekly intervals until the desired level is reached. If dose-dependent effects, such as insomnia, become apparent, the labeled procedure requires the dosage to be reduced. For the long-term usage associated with conditions like ADHD, the treatment protocol specifies that administration should be interrupted occasionally to formally assess the continued need for the medicine.

Age-Group Rules

The official labeling includes specific age restrictions: the medicine is not recommended for use in children under 3 years for ADHD, and not recommended for obesity in children under 12 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Adipan

Evidence for Use in Attention-Deficit Hyperactivity Disorder (ADHD)

The research exploring the substance's use in ADHD includes short-term, placebo-controlled Randomized Controlled Trials (RCTs). Researchers in these studies explored how the medicine may be associated with changes in symptoms, particularly in children and adolescents, but also in adults. These clinical trials were used in research exploring how symptoms change over time, often measuring outcomes related to symptom intensity or variability such as inattention, hyperactivity, and impulsivity using standardized rating scales completed by clinicians, parents, and teachers.

Studies report how symptoms evolved in the observed populations, and trials evaluated patterns related to symptom scores when comparing the active substance to a placebo. Some trials described patterns of rapid change in the assessed symptoms, with changes observed in some studies within the first hour after administration.

Evidence for Use in Narcolepsy and Excessive Daytime Sleepiness

The evidence base for the substance's use in narcolepsy is derived from both early clinical reports and trials, as well as subsequent systematic reviews. This research was studied for its potential role in addressing Excessive Daytime Sleepiness (EDS), a hallmark of the condition. Studies monitored outcomes reflecting daily functioning or activity level, primarily by measuring objective alertness using tests like the Maintenance of Wakefulness Test (MWT).

Research explored how symptoms evolved in the observed populations, and the available data describe patterns related to wakefulness and alertness that were measured in comparison to placebo. Clinical consensus reports describe a long-standing pattern related to the use of the substance for EDS, based on decades of clinical experience and initial trials.

Historical Research in Exogenous Obesity

The research concerning the use of this substance for obesity is primarily historical, dating back to mid-20th-century trials. This was evaluated in short-term controlled clinical trials, where studies monitored outcomes related to systemic or functional imbalance linked to weight management. The historical evidence describes patterns where the observed changes varied and were reliant on the concurrent dietary regimen.

What Remains Uncertain in the Research Landscape

A key uncertainty lies in the durability and maintenance of outcomes over many years, as follow-up durations were limited in the most methodologically rigorous trials. Additionally, the evidence quality varies across studies, particularly between the short-term symptom data and the observational data used for long-term functional effects. Because the findings describe group patterns, not personal outcomes, the existing research provides context but does not determine whether an individual will respond similarly.

Key Studies & References

  1. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents: A systematic review and meta-analysis
  2. Narcolepsy: Evolutions in Pharmacotherapy (Clinical review mentioning amphetamine's role in EDS management)

Frequently Asked Questions (FAQ)

Common questions about Adipan (FAQ)

Q: What is the main reason Adipan is prescribed?

According to official regulatory documents, the medication is approved by the FDA for the treatment of specific medical conditions. These conditions include Attention-Deficit/Hyperactivity Disorder (ADHD) and narcolepsy. The drug is also approved for the short-term treatment of exogenous obesity.

Q: Does Adipan work right away or does it take time to notice a change?

Official product information indicates that the immediate-release tablet form has a relatively quick onset of action. The concentration of the medicine in the blood typically begins to rise within about 30 minutes of taking a dose, reaching a peak around 3 hours.

Q: Are there any common foods or drinks that should be avoided when taking Adipan?

Official labeling notes that certain foods and drinks can affect the drug's absorption. Specifically, consuming gastrointestinal acidifying agents such as fruit juices (like orange or cranberry juice) or high doses of Vitamin C (Ascorbic Acid) may lower the drug's absorption. This decrease in absorption could potentially lead to lower blood levels of the medicine.

Q: Is it common to feel tired or dizzy after starting Adipan?

Official regulatory documentation lists dizziness and a feeling of unusual tiredness or weakness among the reported side effects. While these effects have been documented, their frequency is typically lower compared to the most commonly reported effects, such as dry mouth and insomnia.

Q: What are the results of the main research studies on Adipan?

Clinical trials and research have been conducted to examine changes in symptoms related to its approved uses. Studies examining its use for ADHD have shown it can be associated with reducing core symptoms like inattention and hyperactivity, as well as indications of enhanced quality of life. For narcolepsy, research focuses on outcomes related to improvements in wakefulness and alertness.

Q: How quickly does the body process Adipan?

Information on the drug’s pharmacokinetics describes how the body handles the medicine. For the immediate-release formulation, the average time it takes for the drug concentration to drop by half (the half-life) is approximately 9 to 14 hours. The medicine is primarily processed and eliminated through the kidneys within 24 to 48 hours after administration.

Q: Do studies show Adipan working differently in various populations?

Studies indicate that the way the body processes the medication, specifically the half-life, may differ based on the patient’s age group. Furthermore, official warnings highlight a specific concern regarding the potential for growth suppression (deficits in height and weight) in pediatric patients with long-term use.

Q: Is Adipan used differently for chronic vs. acute conditions?

Yes, regulatory guidance defines the treatment length differently based on the condition being addressed. Its use for chronic conditions like ADHD and narcolepsy is intended to be long-term and ongoing. However, its indication for obesity is officially defined as a short-term treatment regimen.

Q: What is the difference in side effects between Adipan and a placebo in clinical trials?

Official documentation lists the frequency of common side effects reported by patients taking the active drug in clinical studies. For a side effect to be designated as an adverse reaction, the rate reported in the active drug group is generally higher than the rate reported in the placebo group for it to be identified as drug-related.

Q: Can elderly people use Adipan safely?

Official guidance indicates that use in older adults may carry a greater risk for cardiovascular events compared to younger patients. For this reason, official labeling describes the need for careful initial screening for pre-existing conditions and consistent monitoring of blood pressure and heart rate in this population.

Q: Does Adipan require any special monitoring or testing?

Official labeling specifies that regular monitoring is needed during treatment. This monitoring generally includes blood pressure and heart rate due to potential cardiovascular effects. For children on long-term treatment, monitoring of growth (height and weight) is also described as necessary.

Q: Does Adipan have any known interactions with herbal supplements?

Regulatory references state the importance of describing all medications, including any vitamins and herbs, to a healthcare provider. This is noted due to the potential for undocumented interactions between the drug and other compounds.

Q: What happens if Adipan is taken with alcohol?

Official safety information indicates that combining the medication with alcohol can increase the risk of cardiovascular side effects. These serious effects may include an increase in heart rate, changes in blood pressure, and potential chest pain.

Q: Are there any skin reactions or rashes reported with Adipan use?

Yes, official safety documentation lists skin-related issues among the documented side effects. These reported reactions include the occurrence of a skin rash, hives (urticaria), or other forms of red skin lesions.

Q: Can Adipan affect my ability to drive or operate machinery?

Official patient counseling information states that, because the medicine may cause some people to feel dizzy, lightheaded, or less alert, caution is required until an individual knows how the medicine may affect their functioning.

Q: Is Adipan known to interact with caffeine?

Official information on drug-drug and drug-food interactions indicates that combining the medicine with caffeine may enhance cardiovascular effects. This may result in further increases in blood pressure and heart rate beyond the effects of the medicine alone.

Q: Is Adipan a treatment that cures a condition or just manages symptoms?

Clinical reviews describe the drug’s effectiveness for its chronic indications in terms of reducing core symptoms and promoting function, not curing the underlying condition. Its role aligns with symptom management for chronic disorders like ADHD and narcolepsy.

Q: What is the general timeline for discontinuing Adipan?

Official guidance describes that, due to the risk of withdrawal symptoms, the process of discontinuing the drug should involve gradually reducing the dose (tapering). The specific timeline is highly individualized and described as dependent on factors like the patient's dose and the duration of use.

Q: Is Adipan considered a high-alert medication?

The medication is classified by the government as a Schedule II controlled substance, which is the category for drugs with a high potential for abuse and dependence. This classification necessitates strict controls on prescribing, dispensing, and controlled monitoring.

Q: Can I cut or crush Adipan tablets?

Official guidance describes that immediate-release forms may generally be cut or crushed, as they are not designed for sustained release. However, the labeling also specifies that extended-release formulations should not be altered.

Q: What does Adipan's approval status mean for patients?

The medicine is FDA-approved for its listed medical conditions. This regulatory status means that the drug’s safety and effectiveness for those specific uses have been formally reviewed and established by the federal regulatory body.

Q: Are there any known laboratory test interference issues with Adipan?

Yes, official documentation describes potential interference with certain medical tests. The drug is documented to potentially elevate plasma corticosteroid levels and may also interfere with measurements of urinary steroids.

Q: What are the key ingredients in Adipan besides the main compound?

In addition to the active component (amphetamine), the tablets contain inactive ingredients (often called excipients) used in manufacturing the pill. These typically include substances such as microcrystalline cellulose, colloidal silicon dioxide, crospovidone, stearic acid, and talc.

How should Adipan be stored and disposed of?

The official regulatory labeling for Adipan (amphetamine) tablets mandates strict storage and disposal requirements to ensure product quality and security.

Storage Requirements

The tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), protected from freezing, moisture, and light. To comply with controlled substance regulations, the medicine must be dispensed and kept in a well-closed container and stored in a safe, preferably locked place. This is also a mandatory requirement to keep the product out of the sight and reach of children.

Disposal Instructions

When the medication is unused or expired, the proper disposal of the product is required. The preferred method is using a drug take-back program or an authorized collection site. If a take-back option is not available, official guidance instructs that the medicine must be removed from its container, mixed with an undesirable substance (like coffee grounds or dirt), sealed in a bag or container, and discarded in the household trash. The empty packaging must have all personal information scratched out before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Adipan found in:

A-Z Index: